Le Lézard
Classified in: Science and technology, Business
Subject: PDT

AlphaPoint Global Launches Liquidity as a Service with Market Maker Solution


New Turnkey Global Liquidity Solution Enhances the Trading Experience and Provides a Competitive Edge for Exchanges Worldwide

SINGAPORE, Nov. 5, 2024 /PRNewswire/ -- AlphaPoint Global, S.A. de C.V. (APG), the liquidity platform for exchange customers, announced it is launching Liquidity as a Service (LaaS) at the Singapore Fintech Festival, November 6-8, 2024.

AlphaPoint Global's LaaS offering is a powerful algorithmic market making solution built to integrate seamlessly with an exchange's API. The solution will support a broad range of cryptocurrencies and specialized tokens, which are growing as a result of Real World Asset (RWA) tokenization.

APG boasts a veteran team with deep industry knowledge of liquidity solutions for small and growing exchanges worldwide. APG LaaS solution seeks to optimize trading volumes with attractive spreads, enhancing the overall trading experience.

"Liquidity has been one of the biggest challenges for exchanges, especially as they expand into newly created tokens for Real World Assets," said Alex Davidoff, President, AlphaPoint Global. "Since our inception, AlphaPoint Global has a track record as a market maker for digital asset exchanges. Now we are offering a streamlined, turnkey Liquidity as a Service solution that seeks to greatly enhance the trading experience for customers, even in times of high volatility and high user engagement."

Key Benefits for Exchanges:

Unlock Liquidity with These Core Capabilities

To learn more about AlphaPoint Global Liquidity as a Service contact: [email protected] 

About AlphaPoint Global S.A. de C.V. (APG)
AlphaPoint Global provides liquidity solutions to the cryptocurrency market, helping exchanges and institutions access deep, reliable liquidity. AlphaPoint Global seeks to ensure seamless trade execution across a wide range of digital assets by offering a sophisticated, algorithmic market-making solution designed to integrate effortlessly with exchange APIs. AlphaPoint Global's services support a broad array of cryptocurrencies and specialized tokens, enabling exchanges to optimize trading volumes and minimize spreads, enhancing the overall trading experience. For more information, visit apglobal.io.

Disclaimer and other important information regarding the content (including any products and services) described herein

The content provided herein is for informational purposes only. No content provided herein shall be deemed as an offer of services or products from AlphaPoint Global, S.A. de C.V. or any of its affiliates (collectively, "APG") or as an offer to purchase or sell or as the solicitation of an offer to purchase or sell securities, futures, options, or any other investment product. APG disclaims all liabilities regarding the content herein and any use thereof that could be made by any person.

Media Contact:
Alex Davidoff
President
AlphaPoint Global
[email protected] 

SOURCE AlphaPoint Corporation


These press releases may also interest you

at 15:30
Anthony "Tony" Van Heugten, the Chief Technology...

at 15:05
Merck , known as MSD outside of the United States and Canada, today announced the first presentation of data from the Phase 2 waveLINE-007 trial evaluating zilovertamab vedotin, Merck's investigational antibody drug conjugate (ADC) that targets...

at 15:00
AbbVie announced groundbreaking results today from its latest Emotional Impact Report (EIR), a patient survey that provides an understanding of the mental...

at 12:55
Vertex Pharmaceuticals Incorporated today announced longer-term data for CASGEVYtm (exagamglogene autotemcel) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the...

at 12:35
Kite, a Gilead Company , today announced findings from three new analyses for Yescarta® (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), which were...

at 12:35
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today data from a five-year follow-up of the pivotal Phase III POLARIX study evaluating Polivy® (polatuzumab vedotin-piiq) in combination with Rituxan® (rituximab),...



News published on and distributed by: